Levation Pharma Initiates Phase I/II Clinical Trial of LEV102 for Acquired Blepharoptosis
Double Masked, Placebo Control Study at Three Prominent U.S. SitesLOS ANGELES, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Levation Pharma Ltd.,...
Double Masked, Placebo Control Study at Three Prominent U.S. SitesLOS ANGELES, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Levation Pharma Ltd.,...
VANCOUVER, British Columbia and LAS VEGAS, Feb. 27, 2023 (GLOBE NEWSWIRE) -- IV Hydreight Technologies Inc. (TSXV:NURS) (FSE: SO6) (OTCQB:...
Management to host conference call on Monday, March 6 at 4:30 p.m. ETCAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) --...
ZUG, Switzerland and BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative...
CAMBRIDGE, Mass. and NEW YORK, NY, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage...
ATLANTA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is...
SAN CARLOS, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (Nasdaq: APGN) a clinical-stage company focused on developing innovative...
~ Represents a Substantial Milestone in UpHealth’s Focus on Further Integration of its Telehealth, Integrated Care and Behavioral Health Businesses...
Test Delivers Lab-Quality Performance with Results in 30 Minutes or Less – The First At-Home Test to Ever Include Flu...
MORRISTOWN, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development...
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative...
Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer Lyra Therapeutics CTO John Bishop, Ph.D. WATERTOWN, Mass.,...
- Rapid, profound and durable responses across multiple dosing groups with favorable safety profile observed—positioning barzolimab as a potential best-in-class...
FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: eric.nys@financiere-tubize.be Annual Report 2022 Regulated information25 February 2023...
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER,...
ATLANTA, GA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company,” “we,” “us” or “our”) (NYSE American:...
Letter Notifying Customers of Potential Issues with MRidium 1057 MRI Syringe Adapter SetWINTER SPRINGS, Fla., Feb. 24, 2023 (GLOBE NEWSWIRE)...
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on...
Loughborough, England, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology...
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a...